Please assess the completion status of the following clinical trial:

Trial Title: Efficacy And Safety Of The Uro-Ease® Urinary Catheter During Clean Intermittent Catheterization

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CROSSOVER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male patients~* Urinary retention defined as \>150cc retained in bladder on post void residual~Exclusion Criteria:~* Female patients~* Known urethral stricture~* Active symptomatic Urinary Tract Infection~* History of pelvic fracture or urethral disruption~* History of previous urethroplasty(urethral reconstructive surgery)~* Known Latex allergy~* Unable to physically perform CIC~* Unable to provide follow up~* Unable to give consent~* Currently taking chronic narcotic pain medication

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Uro-Ease Spirus Catheter (Type: None): 10 patients randomized to the Uro-Ease Catheter group for 1 week. In clinic, patients will be instructed in the use of the Uro-Ease Catheter. A QOL form will be filled out measuring comfort and ease of use and subsequently after each catheterization. Patients will also record time per catheterization and bladder drainage. Patients will return to Clinic in 1 week to check progress and will then change to a standard, non-helical urinary catheter. Patients will be followed up to 1 month.
- Standard Urinary Catheter (Type: None): 10 patients randomized to a Standard Urinary Catheter group for 1 week. In clinic, patients will be instructed in the use of the catheter. A QOL form will be filled out measuring comfort and ease of use and subsequently after each catheterization. Patients will also record time per catheterization and bladder drainage. Patients will return to Clinic in 1 week to check progress and will then change to the UroEase Spirus Catheter. All patients will be followed up to 1 month.

Based on this trial design, predict the completion outcome and termination type (if applicable).